Market Engagement for Transdermal Capillary Blood Sampling Solutions

Descriptions

This market engagement aims to understand the range of venous‑equivalent transdermal capillary blood sampling devices available to support a shift of diagnostic activity into community and home settings, in line with the ambitions of the 10 Year Health Plan for England. The NHS is exploring how remote blood sampling could alleviate pressures on primary and secondary care phlebotomy services, improve access for underserved populations, and enable earlier diagnosis and management of long‑term conditions. Responses will help bring together local system needs with industry capability and inform future piloting within community pharmacy and other neighbourhood‑based models of care.

Engagement

Background: The 10 Year Health Plan for England (10YHP) sets out a clear ambition to shift care from hospitals into neighbourhood and community settings. Diagnostics are a critical enabler of this shift, ensuring that people can monitor long‑term conditions, receive preventative testing, or be rapidly triaged without needing to attend acute sites. Remote and community‑based blood sampling therefore represents a significant opportunity to improve patient access, support earlier diagnosis, and reduce pressures on primary and secondary care services. This market engagement exercise aims to understand the range of venous‑equivalent transdermal capillary blood sampling devices currently available, and to explore opportunities to pilot their use in community pharmacy settings and potentially in people’s homes. This is particularly important for groups who face barriers to accessing traditional phlebotomy services, including people with learning disabilities, those with needle phobia, homeless populations, and other underserved communities. The insights gained will help bring together local NHS needs with industry expertise, informing how remote sampling could be deployed across priority use cases such as earlier diagnosis and monitoring of long‑term conditions, prescribing support, and improved access for hard‑to‑reach populations. This notice does not constitute a call for competition; rather, it is intended to shape future approaches to remote blood sampling within the NHS. How to participate: Responses should be submitted using the questionnaire link provided here: https://forms.office.com/e/584DXfsXWL Interested organisations are invited to respond to the questions set out in Appendix 1 of the market engagement document. The deadline for responses is 12pm, 3rd March 2026. Further guidance on how to complete the questionnaire and further information about the market engagement, please use this link: https://atamis-1928.my.salesforce.com/sfc/p/0O000000rwim/a/Pz00000HN8G1/DRqaTLc2AL.F4WpKNmtDYEdOkGMqQKTtF_5cyTABlec There is a product specification outline indicated in the market engagement guidance document linked above. Please send any questions relating to this market engagement to england.diagnostics1@nhs.net. Please note that this inbox is for clarification questions only and should not be used for general correspondence. Next Steps: Following the submission deadline we would like to bring respondents together for a roundtable discussion in spring 2026. This will focus on the use cases we are exploring, opportunities to work together to further pilot the use of remote blood sampling within the NHS, and how we can ensure these devices are integrated with NHS labs.